Overcoming mcr-1 mediated colistin resistance with colistin in combination with other antibiotics

Nature Communications

Volumn 9, Issue 1, 2018, Pages

  MacNair, Craig R ^a   Stokes, Jonathan M ^a   Carfrae, Lindsey A ^a   Fiebig Comyn, Aline A ^a   Coombes, Brian K ^a   Mulvey, Michael R ^b   Brown, Eric D ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CLARITHROMYCIN; COLISTIN; MINOCYCLINE; NOVOBIOCIN; PROTEIN MCR 1; RIFABUTIN; RIFAMPICIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ESCHERICHIA COLI PROTEIN; ETHANOLAMINE PHOSPHOTRANSFERASE; MCR-1 PROTEIN, E COLI;

ANTIBIOTIC RESISTANCE; ANTIBIOTICS; BACTERIUM; CELL; CONCENTRATION (COMPOSITION); DRUG RESISTANCE; GENE; GENE EXPRESSION; GROWTH; INHIBITION; LYSIS; PATHOGEN; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTEREMIA; BACTERIAL CELL; BACTERIAL STRAIN; CELL DEATH; CONTROLLED STUDY; DRUG EFFICACY; ENTEROBACTERIACEAE; KLEBSIELLA PNEUMONIAE; LYSIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PLASMID; ANIMAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; GENETICS; KLEBSIELLA INFECTION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

BACTERIA (MICROORGANISMS); ENTEROBACTERIACEAE; KLEBSIELLA PNEUMONIAE; MURINAE; NEGIBACTERIA; POSIBACTERIA;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; COLISTIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; ETHANOLAMINEPHOSPHOTRANSFERASE; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICE; MICROBIAL SENSITIVITY TESTS;

EID: 85041302313     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-018-02875-z     Document Type: Article

References (51)

1. Schindler, M. & Osborn, M. J. Interaction of divalent cations and polymyxin B with lipopolysaccharide. Biochemistry 18, 4425-4430 (1979).
2. Newton, B. A. The properties and mode of action of the polymyxins. Bacteriol. Rev. 20, 14-27 (1956).
3. Jeannot, K., Bolard, A. & Plésiat, P. Resistance to polymyxins in Gram-negative organisms. Int. J. Antimicrob. Agents 49, 526-535 (2017).
4. Cannatelli, A. et al. In vivo emergence of colistin resistance in Klebsiella pneumoniae producing KPC-type carbapenemases mediated by insertional inactivation of the PhoQ/PhoP mgrB regulator. Antimicrob. Agents Chemother. 57, 5521-5526 (2013).
5. Gunn, J. S. The Salmonella PmrAB regulon: lipopolysaccharide modifications, antimicrobial peptide resistance and more. Trends Microbiol. 16, 284-290 (2008).
6. Giani, T. et al. Large nosocomial outbreak of colistin-resistant, carbapenemase-producing Klebsiella pneumoniae traced to clonal expansion of an mgrb deletion mutant. J. Clin. Microbiol. 53, 3341-3344 (2015).
7. Liu, Y.-Y. Y. et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect. Dis. 16, 161-168 (2015).
8. Ye, H. et al. Diversified mcr-1-harbouring plasmid reservoirs confer resistance to colistin in human gut microbiota. MBio 7, e00177 (2016).
9. Falgenhauer, L. et al. Colistin resistance gene mcr-1 in extended-spectrum β-lactamase-producing and carbapenemase-producing Gram-negative bacteria in Germany. Lancet Infect. Dis. 16, 282-283 (2016).
10. Hogg, G. M., Barr, J. G. & Webb, C. H. In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii. J. Antimicrob. Chemother. 41, 494-495 (1998).
11. Giamarellos-Bourboulis, E. J., Xirouchaki, E. & Giamarellou, H. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn. Microbiol. Infect. Dis. 40, 117-120 (2001).
12. Zusman, O. et al. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob. Agents Chemother. 57, 5104-5111 (2013).
13. Timurkaynak, F. et al. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int. J. Antimicrob. Agents 27, 224-228 (2006).
14. Chopra, I. & Hacker, K. Uptake of minocycline by Escherichia coli. J. Antimicrob. Chemother. 29, 19-25 (1992).
15. Pournaras, S. et al. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int. J. Antimicrob. Agents 37, 244-247 (2011).
16. Gordon, N. C., Png, K. & Wareham, D. W. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob. Agents Chemother. 54, 5316-5322 (2010).
17. Rumijowska-Galewicz, A., Lisowska, K., Korycka-Machała, M., Sedlaczek, L. & Ziółkowski, A. Polycations increase the permeability of Mycobacterium vaccae cell envelopes to hydrophobic compounds. Microbiology 147, 2769-2781 (2001).
18. Klinger-Strobel, M., Stein, C., Forstner, C., Makarewicz, O. & Pletz, M. W. Effects of colistin on biofilm matrices of Escherichia coli and Staphylococcus aureus. Int. J. Antimicrob. Agents 49, 472-479 (2017).
19. Lima, T. B. et al. Antibiotic combinations for controlling colistin-resistant Enterobacter cloacae. J. Antibiot. (Tokyo). 70, 122-129 (2016).
20. Kádár, B. et al. Synergistic antibiotic combinations for colistin-resistant Klebsiella pneumoniae. Acta Microbiol. Immunol. Hung. 60, 201-209 (2013).
21. Vidaillac, C., Benichou, L. & Duval, R. E. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Antimicrob. Agents Chemother. 56, 4856-4861 (2012).
22. Zwir, I. et al. Dissecting the PhoP regulatory network of Escherichia coli and Salmonella enterica. Proc. Natl Acad. Sci. USA 102, 2862-2867 (2005).
23. Wright, M. S. et al. Genomic and transcriptomic analyses of colistin-resistant clinical isolates of Klebsiella pneumoniae reveal multiple pathways of resistance. Antimicrob. Agents Chemother. 59, 536-543 (2015).
24. Dobias, J., Poirel, L. & Nordmann, P. Cross-resistance to human cationic antimicrobial peptides and to polymyxins mediated by the plasmid-encoded MCR-1? Clin. Microbiol. Infect. 23, 676.e1-676.e5 (2017).
25. Stokes, J. M. et al. Pentamidine sensitizes Gram-negative pathogens to antibiotics and overcomes acquired colistin resistance. Nat. Microbiol. 2, 17028 (2017).
26. Zhou, Y.-F. et al. Increased activity of colistin in combination with amikacin against Escherichia coli co-producing NDM-5 and MCR-1. J. Antimicrob. Chemother. 72, 1723-1730 (2017).
27. Garonzik, S. M. et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 55, 3284-3294 (2011).
28. Michalopoulos, A. S., Karatza, D. C. & Gregorakos, L. Pharmacokinetic evaluation of colistin sodium. Expert Opin. Drug. Metab. Toxicol. 7, 245-255 (2011).
29. Plachouras, D. et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob. Agents Chemother. 53, 3430-3436 (2009).
30. Drusano, G. L. et al. Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination. Antimicrob. Agents Chemother. 30, 42-45 (1986).
31. Esposito, S. et al. Hot topics in the diagnosis and management of skin and soft-tissue infections. Int. J. Antimicrob. Agents 48, 19-26 (2016).
32. MacNair, C. R. et al. A cell-based approach to characterize antimicrobial compounds through kinetic dose response. Bioorg. Med. Chem. 24, 6315-6319 (2016).
33. Rasko, D. A. & Sperandio, V. Anti-virulence strategies to combat bacteria-mediated disease. Nat. Rev. Drug Discov. 9, 117-128 (2010).
34. Package insert: Colistimethate for injection (Coly-mycin M Parenteral). JHP Pharmaceuticals, LLC, Rochester, MI 48307. Revised February 2011.
35. Package insert: BIAXIN® Filmtab® (clarithromycin tablets, USP). Abbott Pharmaceuticals PR Ltd, Barceloneta, PR 00617 (2012).
36. Powers, J. P. S. & Hancock, R. E. W. The relationship between peptide structure and antibacterial activity. Peptides 24, 1681-1691 (2003).
37. Vaara, M. Effect of ionic strength on polymyxin resistance of pmrA mutants of Salmonella. Fems Microbiol. Lett. 11, 321-325 (1981).
38. Salazar, J., Alarcón, M., Huerta, J., Navarro, B. & Aguayo, D. Phosphoethanolamine addition to the Heptose I of the Lipopolysaccharide modifies the inner core structure and has an impact on the binding of Polymyxin B to the Escherichia coli outer membrane. Arch. Biochem. Biophys. 620, 28-34 (2017).
39. Nikaido, H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol. Mol. Biol. Rev. 67, 593-656 (2003).
40. Soon, R. L. et al. Design, synthesis, and evaluation of a new fluorescent probe for measuring polymyxin-lipopolysaccharide binding interactions. Anal. Biochem. 409, 273-283 (2011).
41. Velkov, T. et al. Surface changes and polymyxin interactions with a resistant strain of Klebsiella pneumoniae. Innate Immun. 20, 350-363 (2014).
42. Vaara, M. & Vaara, T. Sensitization of Gram-negative bacteria to antibiotics and complement by a nontoxic oligopeptide. Nature 303, 526-528 (1983).
43. Hancock, R. E. & Chapple, D. S. Peptide antibiotics. Antimicrob. Agents Chemother. 43, 1317-1323 (1999).
44. Velkov, T., Thompson, P. E., Nation, R. L. & Li, J. Structure-activity relationships of polymyxin antibiotics. J. Med. Chem. 53, 1898-1916 (2010).
45. Tzeng, Y. L. et al. Cationic antimicrobial peptide resistance in Neisseria meningitidis. J. Bacteriol. 187, 5387-5396 (2005).
46. Baba, T. et al. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol. Syst. Biol. 2, 2006.0008 (2006).
47. CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard Tenth Edition. CLSI document M07-A10 (2015).
48. Jenkins, S. G. & Schuetz, A. N. Current concepts in laboratory testing to guide antimicrobial therapy. Mayo Clinic Proceedings 87, 290-308 (2012).
49. Helander, I. M. & Mattila-Sandholm, T. Fluorometric assessment of Gram-negative bacterial permeabilization. J. Appl. Microbiol. 88, 213-219 (2000).
50. Wang, J. et al. High specific selectivity and membrane-active mechanism of the synthetic centrosymmetric α-helical peptides with Gly-Gly pairs. Sci. Rep. 5, 15963 (2015).
51. King, A. M. et al. Aspergillomarasmine A overcomes metallo-β-lactamase antibiotic resistance. Nature 510, 503-506 (2014).